Select text to enable text to speech.

Resources

Restore Vision set image

Newsletter

Newsletter #1 November 2024

Read Restore Vision’s first newsletter!

Read more

Screenshot 2024-09-18 142913

Flyer

Advancing Treatments for Rare Eye Diseases in Europe – Restore Vision Flyer

The Restore Vision project in a nutshell.

Read more

RestoreV2

Poster

Fine Needle Diathermy with and without Antisense Oligonucleotide Eye Drops Against Insulin Receptor Substrate-1

Wei Zhang, Zhe Chen1, Mert Mestanoglu, Shuyu Hu, Felix Bock, Claus Cursiefen

Read more

claus

Poster

Pilot Human Data on High-Risk Keratoplasty Combined with Fine Needle Diathermy and Corneal Crosslinking for Regression of Pathological Corneal Neovascularization

Claus Cursiefen; Mert Mestanoglu, Heide Heinen, Johanna Wiedemann, Felix Bock; Björn Bachmann, Deniz Hos

Read more

UKK_poster

Poster

The Aey80 Mutation in the Pax 6 Gene Causes an Age-dependent Aniridia Phenotype

Karina Hadrian; W Zhang; M Mestanoglu; T Volatie1; OV Amarie; M Hrabe de Angelis; F Bock; C Cursiefen

Read more

Physicochemical characterization_RaquelGregorio_page-0001

Poster

Physicochemical characterization of new medical-grade spironolactone formulations for the anterior and posterior segments of the eye

Raquel Gregorio Arribada; Daniela Rodrigues-Braz; Dan Mejlachowicz; Youcef Benzine; Phillipe Rampignon; Min Zhao; Francine Behar-Cohen.

Read more

Efficacy_of_new_eyedrop_DanielaBraz_page-0001

Poster

Efficacy of a new hydroxypropyl-gamma-cyclodextrin-based eyedrop of spironolactone in a rat model of corneal wound healing

Daniela Rodrigues-Braz, Linxin Zhu, Emmanuelle Gélizé, Jean-Pierre Clarin, Xavier Chatagnon, Youcef Benzine, Philippe Rampignon, Jean-Louis Bourges, Francine Behar-Cohen, Min Zhao.

Read more

Screenshot (490)

Webinars

Restore Vision Webinar

Watch the recording from Restore Vision first webinar. Learn more about the project and the observational study conducted at Ospedale San Rafaelle in Milan.

Read more

Interested in Restore vision?

Stay informed about our efforts to combat rare eye diseases and bring new hope to those affected by visual impairment by subscribing to our newsletter for updates on our latest treatments and research.